uniQure (QURE) Shares Soar On Positive Medical Trial News
In recent trading sessions, UniQure (NASDAQ: QURE) shares have soared by 56.15% to $10.41, bolstered by optimistic interim findings from ongoing clinical trials. The data highlights a notable slowdown in disease progression and reduced neurofilament light chain (NfL) levels, crucial markers in Huntington’s disease. Long-term Therapeutic Potential and Regulatory Pathway Advancements UniQure explores a unique […]
uniQure (QURE) Shares Soar On Positive Medical Trial News Read More »